Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Retatrutide is an investigational agent that produces very large body-weight reductions in early trials by simultaneously engaging GLP-1R, GIPR, and GCGR to enhance satiety, energy expenditure, and glycemic control2575, Thymosin Beta-4 promotes wound healing, angiogenesis, and tissue regeneration in preclinical models via effects on cytoskeleton dynamics, cell migration, and anti-apoptotic pathways25579.
While Retatrutide works as a triple incretin agonist peptide derived from a GIP backbone and engineered to activate GLP-1, GIP, and glucagon receptors, with non-natural residues and fatty-acid conjugation that confer long half-life and balanced multi-receptor signaling256575, Thymosin Beta-4 is an endogenous 43-amino-acid actin-sequestering peptide that maintains a pool of G-actin monomers and regulates actin polymerization, thereby influencing cell migration, proliferation, and differentiation25579.
Retatrutide
Not assigned in the current dataset.
Thymosin Beta-4
TMSB4X
Retatrutide and Thymosin Beta-4 are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: Retatrutide is more often discussed in the realm of Metabolic and endocrine, whereas Thymosin Beta-4 is more often associated with the realm of Musculoskeletal health, Cardiovascular health, and Dermatology and aesthetics. Their biological logic is quite different: Retatrutide is a receptor agonist and a hormone analog, whereas Thymosin Beta-4 is a signaling modulator and a protein interaction inhibitor. Retatrutide has a more synthetic analog origin, while Thymosin Beta-4 is closer to natural endogenous background with Retatrutide in Clinical phase 3 and Thymosin Beta-4 in Clinical phase 2. Retatrutide takes the form of a peptide conjugate, whereas Thymosin Beta-4 is closer to a linear peptide, Retatrutide carries lipidation features, while Thymosin Beta-4 instead reflects acetylation changes; while their sequence patterns also diverge, with Retatrutide showing alpha-helical domain features and Thymosin Beta-4 showing protein-mimetic sequence features.